RARE Latest Press Releases

-- January 30, 2026 --

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA Globe Newswire 8:30 AM

-- January 29, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE PRNewswire 10:00 AM

-- January 27, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE Globe Newswire 1:28 PM

-- January 23, 2026 --

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies PRNewswire 2:05 PM

-- January 22, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE PRNewswire 10:00 AM

-- January 15, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE PRNewswire 10:00 AM

-- January 13, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE Globe Newswire 4:12 PM

-- January 12, 2026 --

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference Globe Newswire 7:30 AM

-- January 8, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE PRNewswire 10:00 AM

-- January 7, 2026 --

Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 4:05 PM

-- January 6, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE Globe Newswire 12:42 PM

-- December 30, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE Globe Newswire 4:29 PM

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) Globe Newswire 4:05 PM

Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm Globe Newswire 2:25 PM

-- December 29, 2025 --

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta Globe Newswire 8:30 AM

-- December 19, 2025 --

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- November 24, 2025 --

Ultragenyx to Participate in Investor Conferences in December Globe Newswire 4:30 PM

-- November 21, 2025 --

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- November 4, 2025 --

Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update Globe Newswire 4:05 PM

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita (burosumab) for $400 Million to OMERS Life Sciences Globe Newswire 4:01 PM

-- October 30, 2025 --

Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups Globe Newswire 8:00 AM

-- October 28, 2025 --

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update Globe Newswire 4:30 PM

-- October 24, 2025 --

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- October 3, 2025 --

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- September 30, 2025 --

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President Globe Newswire 4:05 PM

-- September 19, 2025 --

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- September 8, 2025 --

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) Globe Newswire 4:05 PM

-- September 3, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE PRNewswire 10:00 AM